Logo image of CANF

CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Fundamental Analysis

USA - NYSEARCA:CANF - US13471N3008 - ADR

0.4613 USD
-0.02 (-4.43%)
Last: 10/24/2025, 8:12:18 PM
0.4635 USD
+0 (+0.48%)
After Hours: 10/24/2025, 8:12:18 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CANF. CANF was compared to 534 industry peers in the Biotechnology industry. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability. CANF has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CANF had negative earnings in the past year.
In the past year CANF has reported a negative cash flow from operations.
CANF had negative earnings in each of the past 5 years.
CANF had a negative operating cash flow in each of the past 5 years.
CANF Yearly Net Income VS EBIT VS OCF VS FCFCANF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

CANF has a worse Return On Assets (-102.07%) than 75.84% of its industry peers.
CANF has a worse Return On Equity (-188.34%) than 65.54% of its industry peers.
Industry RankSector Rank
ROA -102.07%
ROE -188.34%
ROIC N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
CANF Yearly ROA, ROE, ROICCANF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CANF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CANF Yearly Profit, Operating, Gross MarginsCANF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
CANF has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CANF has been increased compared to 5 years ago.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CANF Yearly Shares OutstandingCANF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
CANF Yearly Total Debt VS Total AssetsCANF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

CANF has an Altman-Z score of -32.19. This is a bad value and indicates that CANF is not financially healthy and even has some risk of bankruptcy.
CANF has a worse Altman-Z score (-32.19) than 89.89% of its industry peers.
CANF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -32.19
ROIC/WACCN/A
WACC8.79%
CANF Yearly LT Debt VS Equity VS FCFCANF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

CANF has a Current Ratio of 3.60. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
CANF has a Current ratio (3.60) which is comparable to the rest of the industry.
CANF has a Quick Ratio of 3.60. This indicates that CANF is financially healthy and has no problem in meeting its short term obligations.
CANF has a Quick ratio (3.60) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
CANF Yearly Current Assets VS Current LiabilitesCANF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

CANF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.00%, which is quite impressive.
Looking at the last year, CANF shows a decrease in Revenue. The Revenue has decreased by -9.29% in the last year.
Measured over the past years, CANF shows a very negative growth in Revenue. The Revenue has been decreasing by -19.81% on average per year.
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%-36.08%

3.2 Future

The Earnings Per Share is expected to grow by 50.44% on average over the next years. This is a very strong growth
CANF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 203.73% yearly.
EPS Next Y13.95%
EPS Next 2Y50.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y203.73%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CANF Yearly Revenue VS EstimatesCANF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
CANF Yearly EPS VS EstimatesCANF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2023 2024 2025 2026 0 200 -200 -400 -600 -800

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CANF. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 0.00, the valuation of CANF can be described as very cheap.
Based on the Price/Forward Earnings ratio, CANF is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.92, CANF is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0
CANF Price Earnings VS Forward Price EarningsCANF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CANF Per share dataCANF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100 150 200 250

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CANF's earnings are expected to grow with 50.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.44%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CANF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAN FITE BIOPHARMA LTD-ADR

NYSEARCA:CANF (10/24/2025, 8:12:18 PM)

After market: 0.4635 +0 (+0.48%)

0.4613

-0.02 (-4.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2025-08-28
Earnings (Next)04-12 2026-04-12/bmo
Inst Owners3.34%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap7.88M
Revenue(TTM)674.00K
Net Income(TTM)-7880000
Analysts82.86
Price Target6.38 (1283.05%)
Short Float %0.86%
Short Ratio0.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.81%
PT rev (3m)-22.24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)22.13%
EPS NY rev (3m)-18.27%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0
P/S 11.69
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 1.88
EV/EBITDA N/A
EPS(TTM)-0.72
EYN/A
EPS(NY)256.84
Fwd EY55677.21%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.04
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -102.07%
ROE -188.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.8%
ROA(5y)-101.33%
ROE(3y)-164.91%
ROE(5y)-170%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.9%
Cap/Sales 0.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -32.19
F-Score3
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)49.68%
Cap/Depr(5y)88.86%
Cap/Sales(3y)0.71%
Cap/Sales(5y)1.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y13.95%
EPS Next 2Y50.44%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.29%
Revenue growth 3Y-7.55%
Revenue growth 5Y-19.81%
Sales Q2Q%-36.08%
Revenue Next Year0%
Revenue Next 2Y-10.92%
Revenue Next 3Y203.73%
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.49%
OCF growth 3YN/A
OCF growth 5YN/A

CAN FITE BIOPHARMA LTD-ADR / CANF FAQ

Can you provide the ChartMill fundamental rating for CAN FITE BIOPHARMA LTD-ADR?

ChartMill assigns a fundamental rating of 3 / 10 to CANF.


Can you provide the valuation status for CAN FITE BIOPHARMA LTD-ADR?

ChartMill assigns a valuation rating of 4 / 10 to CAN FITE BIOPHARMA LTD-ADR (CANF). This can be considered as Fairly Valued.


Can you provide the profitability details for CAN FITE BIOPHARMA LTD-ADR?

CAN FITE BIOPHARMA LTD-ADR (CANF) has a profitability rating of 0 / 10.


What is the expected EPS growth for CAN FITE BIOPHARMA LTD-ADR (CANF) stock?

The Earnings per Share (EPS) of CAN FITE BIOPHARMA LTD-ADR (CANF) is expected to grow by 13.95% in the next year.